1. Introduction {#sec1}
===============

Malaria is the most important vector-borne disease and remains a preeminent global public health problem. In 2016, 91 countries reported approximately 216 million cases of malaria and a global death toll of about 445,000 ([@bib39]) African countries, especially in sub-Saharan Africa, account for 90% of malaria cases and deaths ([@bib39]) The majority of human malaria is caused by five species, namely, *Plasmodium falciparum*, *Plasmodium vivax*, *Plasmodium malaria*, *Plasmodium ovale* and *Plasmodium knowelsi* ([@bib23]). In Africa, *P. falciparum* is the predominant species of malaria ([@bib39]).

Malaria used to be one of the most important infectious disease in China ([@bib19]). Since the Chinese Government initiated the National Malaria Elimination Program in 2010, malaria transmission has obviously been reduced. There has been no indigenous cases reported in China since 2017 ([@bib44]). However, migrant workers and travelers between China and other countries have increased in recent years. Hence, imported malaria cases have markedly increased in the Guangxi Zhuang Autonomous Region. And the most of imported cases were *P. falciparum* from Africa ([@bib44]). An outbreak of imported malaria took place in 2013 in Shanglin, Guangxi Zhuang Autonomous Region ([@bib38]).

Sulfadoxine-pyrimethamine (SP) is no longer used for treatment of clinical malaria in Africa because of widespread resistance ([@bib8]; [@bib33]). However, it continues to be used as an intermittent preventive treatment during pregnancy (IPTp) in malaria-endemic areas in Africa. In sub-Saharan Africa, IPTp-SP has been shown to reduce maternal anemia, low birth weight and perinatal mortality ([@bib41]). Seasonal malaria chemoprevention (SMC) with amodiaquine (AQ) plus SP (AQ + SP) for children aged 3--59 months reduces the incidence of clinical attacks and severe malaria by about 75% ([@bib41]). SP is also provided as intermittent preventive treatment in infants (IPTi) in areas of moderate-to-high malaria transmission of Africa, however, no countries have reported implementation of an IPTi policy as of 2015, Sierra Leone began implementing IPTi on a pilot basis in one district in 2016 ([@bib39], [@bib40], [@bib41]). WHO is calling on all malaria-affected countries in sub-Saharan Africa and their development partners to adopt and implement IPTi-SP ([@bib40]). Yet the decline in the efficacy of SP had already emerged in Africa, and levels of SP resistance vary within Africa ([@bib26]), boding ill for the future.

To inform current policy on continuing use of SP, surveillance of SP resistance levels must be achieved by monitoring of molecular markers and by describing its geographical distribution. SP resistance is linked with dihydrofolate reductase (*dhfr*) in the folate biosynthetic pathway, and substitutions of amino acids in the enzymes dihydropteroate synthetase (*dhps*) ([@bib2]). Resistance to SP is caused by point mutations in the *dhfr* and *dhps* genes of *P. falciparum* ([@bib32]). In the *dhfr* gene, the mutations N51I, C59R, S108N and I164L are associated with pyrimethamine resistance ([@bib7]; [@bib30]). In the *dhps* gene, mutations have been identified in codons 436, 437, 540, 581 and 613 that confer resistance to dihydropteroate ([@bib4]; [@bib37]). The combination of a triple *dhfr* (N51I/C59R/S108N) mutant with a double *dhps* (A437G/K540E) mutant is a useful predictor of clinical SP treatment failure and results in limited efficacy of SP-IPTi ([@bib17]). The triple mutant *pfdhfr* with the *pfdhps* single mutant 437G also has been found to be associated with treatment failure in Western and Central Africa ([@bib18]; [@bib10]; [@bib31]). In addition, the WHO recommended that SP-IPTi should not be implemented when the prevalence of *dhps* K540E exceeds 50% ([@bib15]). A recent meta-analysis demonstrated that IPTp efficacy was reduced when the prevalence of A581G exceeds 10% in Africa ([@bib6]). This situation may suggest discontinuation of IPTp. In some parts of East Africa, other findings reported that SP-IPTi and IPTp have failed in the quintuple mutant (N51I/C59R/S108N + A437G/K540E) acquired *pfdhps* A581G ([@bib31]; [@bib13]). According to reports, an unusual I431V mutation in *dhps* gene has been seen to emerge in combination with A436S, A437G, A581G and A613S in Africa ([@bib36]; [@bib28]). Although there was no available data show that higher SP resistance is associated with an increasing number of these mutations, these mutations do favor resistance risk.

In Western Africa and Central Africa, the combination of *dhfr* N51I, N59R, and S108N with *dhps* A437G has been demonstrated to be prevalent ([@bib26]). However, we know little about drug resistance imported from Western Africa to China in recent years ([@bib43]; [@bib42]). Therefore, we evaluated polymorphisms and the geographic distribution of haplotypes of *pfdhfr* and *pfdhps* imported to China from Western Africa, which would help provide information on imported *P. falciparum* malaria cases in China and future treatment policy with IPTp for the two clinical populations.

2. Methods {#sec2}
==========

2.1. Samples collection and DNA extraction {#sec2.1}
------------------------------------------

Blood samples were obtained from malaria cases who returned from Africa to Guangxi Province, China between 2016 and 2018. Malaria infections were diagnosed by microscopic examination of Giemsa-stained thick and thin blood films. The questionnaires of all cases were recorded, including gender, ethnicity, occupation, microscopic examination results and travel history. The human subject protocol for this study was by the Shanglin Hospital Institutional Review Board. All participants supplied written informed consent. Prospective cases with complex travel histories were excluded from the study.

Parasite DNA was extracted from whole blood using the High Pure PCR Template Preparation Kit (Roche) according to the manufacturer\'s instructions. Then *P. falciparum* infection was confirmed using a nested polymerase chain reaction (PCR) targeting the small subunit ribosomal RNA gene as described previously ([@bib34]; [@bib35]). The DNA template was kept at −20 °C until use.

2.2. Amplification and sequencing of *pfdhfr* and *pfhhps* gene {#sec2.2}
---------------------------------------------------------------

Only infections containing strains *P. falciparum* by genotyping were used for sequencing analysis. Those associated with resistance to SP were investigated by examining four codons of *pfdhfr* (N51I, C59R, S108N and I164L) and six codons of *pfdhps* (I431V, S436 A/F, A437G, K540 E/N, A581G and A613T) ([@bib7]; [@bib30]; [@bib4]; [@bib37]). The *pfdhfr* and *pfdhps* gene were amplified using primers and conditions as described earlier ([@bib12]). Briefly, primary PCR was performed in a total volume of 20 μL containing 2 μL DNA template, 10 μL Premix Taq Version 2.0 (TakaRa, USA), 1  μL of each primer, and 6 μl ddH2O. The secondary PCR was performed in a total volume of 40 μL containing 2  μL primary PCR product, 20 μL Premix Taq Version 2.0 (TakaRa, USA), 1  μL of each primer, and 19 μL ddH2O. Positive PCR products were sequenced by Generalbiol (Chuzhou, China). The forward and reverse sequences were aligned using DNASTAR (version 7.1) software and were manually refined to obtain a better consensus nucleotide sequence. The consensus sequences of *pfdhfr* and *pfdhps* gene were multiple-aligned with a reference sequence of the gene retrieved from the GeneBank database using BioEdit (version 7.2.5). The GeneBank accession numbers of the *pfdhfr* and *pfdhps* reference sequences were PF3D7_0417200.1 and PF3D7_0810800.1, respectively. The nucleotide sequences of the multiple alignments for each gene were translated into their corresponding amino acid sequences and manually analyzed for mutations at the specified codons.

2.3. Statistical analysis {#sec2.3}
-------------------------

Statistical analysis was carried out with the SPSS software (version 22). The chi-square test was used to compare the categorical variables among the groups. A *p*-value of \<0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Characteristics of study participants {#sec3.1}
------------------------------------------

A total of 243 *P. falciparum* cases returning to Guangxi Province from 8 countries of Africa between March 2016 and September 2018 were enrolled in this study. These patients returned from four countries in Western Africa (78.6%, 191/243): Liberia, Sierra Leone, Mali, Ghana, and four countries located in Central Africa (21.4%, 52/243): Congo, Cameroon, the Democratic Republic of the Congo (DRC), Central African Republic ([Fig. 1](#fig1){ref-type="fig"}). Most of those from Ghana came from Kumasi or Asankragua. There were 235 male patients and 8 female patients. The distribution of patients by age ranged from 15 to 64, the mean age was 38.9 ± 9.9 years. All patients received targeted antimalarial treatment according to the guidelines of antimalarial drugs in China.Fig. 1Map of isolates returned from Central Africa and Western Africa.Fig. 1

3.2. *P. falciparum pfdhfr* gene analysis {#sec3.2}
-----------------------------------------

A total of 208 cases were successfully sequenced for codons 51, 59, 108, 164 of *pfdhfr* gene, 165 in Western African and 43 in Central Africa. A high prevalence of *Pfdhfr* mutant isolates was observed in this study. The *pfdhfr* mutations at codons 51, 59 and 108 were prevalent in each geographic region (\>85%) ([Table 1](#tbl1){ref-type="table"}). In addition, C59R and S108N were near saturation in our study. The I164L mutant was present, but rare, with no evident regional difference between Western and Central Africa (P \> 0.05).Table 1Prevalence distribution of *pfdhfr* and *pfdhps* gene mutations among two groups.Table 1GeneCodon% (n) of isolates*P*Western AfricaCentral Africa*pfdhpr*N = 165N = 43N51I86.1 (142)90.7 (39)0.611C59R90.3 (149)93.0 (40)0.799S108N93.3 (154)93.0 (40)1I164L11.5 (19)4.7 (2)0.295*pfdhps*N = 147N = 40I431V0.7 (1)0.0 (0)1.000S436 A/F57.1 (84)45.0 (18)0.211A437G87.8 (129)70.0 (28)0.015\*K540 E/N12.9 (19)10.0 (4)0.820A581G11.6 (17)0.0 (0)0.052A613 S/T10.9 (16)5.0 (2)0.414[^2]

The genotypes of *pfdhfr* are presented in [Table 2](#tbl2){ref-type="table"}. About 165 isolates returned from 4 countries in Western Africa followed 5 haplotypes. Only 11 of 165 isolates (6.67%) were wild type N~51~C~59~S~108~I~164~, meaning nearly 95% harbored at least one mutation. The most prevalent of these (71.5%) was the triple-mutant haplotype triple-mutant haplotype **IRN**I, followed by a quadruple-mutant **IRNL** (11.5%), and two double mutants **I**C**N**I (3.0%) and N**RN**I (7.3%). As in Western Africa, wild-type haplotypes were only infrequently encountered in the 43 isolates derived from Central Africa 7%), Here too, the triple-mutant **IRN**I was also by far the most prevalent (86.1%). Other haplotypes included the quadruple-mutant **IRNL** (4.7%) and the double-mutant N**RN**I (2.3%). In addition, the double-mutant N**RN**I was only detected in five patients who returned from Ghana, Western Africa. Significant differences among groups were not observed with these mutations (P \> 0.05). No mixed haplotypes were identified.Table 2Prevalence of *Pfdhfr* and *Pfdhps* haplotypes in isolates.Table 2GeneHaplotypeTotal*Western Africa*Total*Central AfricaP*[a](#tbl2fna){ref-type="table-fn"}Liberia\
% (n)Sierra Leone\
% (n)Mali\
% (n)Ghana\
% (n)Congo\
% (n)Cameroon\
% (n)Congo, DRC\
% (n)Central African\
Republic\
% (n)*pfdhfr*N = 165N = 7N = 3N = 1N = 154N = 43N = 10N = 24N = 5N = 4NCSI (WT)6.7 (11)00100.00 (1)6.5 (10)7.0 (3)10.00 (1)8.3 (2)000.792**I**C**N**I3.0 (5)0003.3 (5)000000.551N**RN**I7.3 (12)14.3 (1)100 (3)05.2 (8)2.3 (1)10.00 (1)0000.401**IRN**I71.5 (118)85.7 (6)0072.7 (112)86.1 (37)70.00 (7)91.7 (22)80.0 (4)100.0 (4)0.051**IRNL**11.5 (19)00012.3 (19)4.7 (2)10.00 (1)020.0 (1)00.295  *pfdhps*N = 147N = 8N = 3N = 1N = 135N = 40N = 4N = 25N = 6N = 5ISAKAA (WT)1.4 (2)1.3 (1)000.74 (1)5.0 (2)08.0 (2)000.201I**A/F**AKAA8.8 (13)033.3 (1)08.9 (12)22.5 (9)032.0 (8)020.0 (1)0.036\*IS**G**KAA29.3 (43)50.0 (4)33.3 (1)100.0 (1)27.4 (37)40.0 (16)040.0 (10)83.3 (5)20.0 (1)0.195I**AG**KAA36.1 (53)37.5 (3)0037.0 (50)17.5 (7)016.0 (4)4.0 (1)40.0 (2)0.026\*I**A/F**AKA**S**2.0 (3)0002.2 (3)2.5 (1)00020.0 (1)1IS**GE**AA2.7 (4)033.3 (1)02.2 (3)10.0 (4)100.00 (4)0000.115I**AG**K**G**A1.4 (2)0001.4 (2)000001I**AG**KE**S**7.5 (11)0008.2 (11)2.5 (1)04.0 (1)000.438IS**GN/EG**A8.8 (13)0009.6 (13)000000.11I**AGE**AA0.7 (1)0000.7 (1)000001IS**GEGS**0.7 (1)0000.7 (1)000001**VAG**K**GS**0.7 (1)0000.7 (1)000001[^3][^4]

3.3. Analysis of *pfdhps* gene {#sec3.3}
------------------------------

The *pfdhps* gene was successfully sequenced in 147 Western African and 40 Central African isolates. The prevalence distribution of the *pfdhps* mutation is summarized in [Table 1](#tbl1){ref-type="table"}. None of which were entirely wild-type.

The I431V and A581G mutant allele were observed only from Ghana in Western Africa. The most frequent *pfdhps* mutation (A437G) was prevalent everywhere, but significantly more so in Western Africa (87.8%) than in Central Africa (70.0%) (χ^2^ = 5.966, P \< 0.05).

Fifteen different genotypes were found in patients returned from Western Africa ([Table 2](#tbl2){ref-type="table"}). Prevalence of the wild-type haplotype did not significantly vary regionally. In Western Africa, the double-mutant I**AG**KAA was most common in patients who returned from Ghana. It was significantly higher in Western than Central Africa (χ^2^ = 4.968, *P* \< 0.05). There were 7 different genotypes of *pfdhps* gene found in patients returned from Central Africa. The common genotype was IS**G**KAA. In addition, single-mutant haplotypes I**A/F**AKAA was significantly higher in Central Africa than Western Africa (χ^2^ = 4.410, *P* \< 0.05).

3.4. *Pfdhfr* and *pfdhps* haplotypes analysis {#sec3.4}
----------------------------------------------

As summarized in [Table 3](#tbl3){ref-type="table"}, multiple mutations that contribute to SP resistance in both *pfdhfr* and *pfdhps* genes were detected in this study, comprising more than twenty *pfdhfr/pfdhps* haplotypes, none of which were entirely wild-type. The quadruple mutant I**A**AKAA/**IRN**I was significantly higher in Central Africa (χ^2^ = 8.623, P \< 0.05). The quadruple mutant (I**A**AKAA/**IRN**I) was presented in high proportion (42.1%) in Cameroon, Central Africa. However, the quintuple mutant (I**AG**KAA/**IRN**I) haplotypes were significantly higher in Western Africa than Central Africa (χ^2^ = 7.801, P \< 0.05). Results showed that a prevalence of 46.2% (42/91) *pfdhfr/pfdhps* quintuple (I**AG**KAA/**IRN**I) was especially prevalent in patients returned from Ghana, Western Africa. However, the quadruple mutant (I**A**AKAA/**IRN**I) was presented in high proportion (42.1%) in Cameroon, Central Africa.Table 3Prevalence of *Pfdhfr*/*Pfdhps* genotype.Table 3GeneNo. of mutationsTotalWestern AfricaTotalCentral Africa*P*[a](#tbl3fna){ref-type="table-fn"}*pfdhfr/pfdhps genetype*Liberia\
% (n)Sierra Leone % (n)Ghana\
% (n)Congo\
% (n)Congo, DRC\
% (n)Cameroon\
% (n)N = 98N = 5N = 2N = 91N = 21N = 1N = 1N = 19IA**G**KAA/NCSI100004.8 (1)005.3 (1)0.394I**AG**KAA/NCSI200004.8 (1)005.3 (1)0.394IS**G**KAA/N**RN**I34.1 (4)20.0 (1)03.3 (3)4.8 (1)005.3 (1)1ISAKAA/**IRN**I31.0 (1)20.0 (1)009.5 (2)0010.5 (2)0.137I**A**AKAA/N**RN**I32.0 (2)002.2 (2)00001I**AG**KA**S/**N**RN**I42.0 (2)002.2 (2)00001I**AG**KAA/N**RN**I41.0 (1)001.1 (1)00001I**AG**KAA/**I**C**N**I44.1 (4)004.4 (4)00000.794I**A**AKAA/**IRN**I410.2 (10)050.00 (1)9.9 (9)38.1 (8)0042.1 (8)0.003\*I**A/F**AKA**S**/**IRN**I52.0 (2)002.2 (2)4.8 (1)005.3 (1)0.445I**AG**KAA/**IRN**I545.9 (45)60.0 (3)046.2 (42)14.3 (3)050.0 (1)10.5 (2)0.001\*IS**GE**AA/**IRN**I53.1 (3)050.00 (1)2.2 (2)14.3 (3)0015.7 (3)0.113IS**GE**AA/**IRNL**500004.8 (1)50.0 (1)00--I**AG**KA**S**/**IRN**I59.2 (9)009.9 (9)00000.322I**AG**K**G**A/**IRN**I62.0 (2)002.2 (2)00001IS**GNG**A/**IRN**I61.0 (1)001.10 (1)00001I**AGE**AA/**IRN**I61.0 (1)001.10 (1)00001IS**GEG**A/**IRNL**79.2 (9)009.9 (9)00000.322**V**A**G**K**GS/IRN**I71.0 (1)001.10 (1)00001IS**GEGS**/**IRN**I71.0 (1)001.10 (1)00001[^5][^6]

4. Discussion {#sec4}
=============

The evolution and widespread dissemination of malarial resistance to sulfadoxine-pyrimethamine has restricted its clinical use in Africa to intermittent preventive treatment during pregnancy (IPTp), in infants (IPTi) and SMC ([@bib8]; [@bib33]). In 2016, 15 million children in 12 countries in Africa\'s Sahel subregion were protected through SMC ([@bib41]). Among 39 African countries on IPTp in 2017, about 22% of pregnant women received three or more doses of IPTp, compared with 17% in 2015 and 0% in 2010 ([@bib41]). Current guidelines in China call for the use of ACT treatment ([@bib24]). For uncomplicated *P. falciparum* patients, ACTs routinely include oral compound tablets of dihydroarte-misinin plus piperaquine (DHA + PQ), artesunate plus amodiaquine (AS + AQ), and ART + PQ ([@bib25]). All patients in this study were treated with intravenous (IV) injections of artesunate for 3 days (on day 0 with 120 mg, and 60 mg on subsequent 2 days) in the hospital. Upon resolution of their symptoms, patients were discharged and two days of oral treatment with dihydroartemisinin-piperaquine (DHP) was prescribed.

Our purpose was to better understand the spectrum of malarial parasites being imported to China from Africa, where such resistance is widespread, in order to shed light on clinical options and limitations for such patients, and to assess risks associated with the spread of resistant malarial parasites. Such molecular epidemiology is needed in order to elucidate dynamic epidemiological features and to provide policy makers with information needed to develop better safeguards for such travelers and for the populations to which they return. Unfortunately, we cannot determine from these data, whether in the same locality, certain resistance haplotypes are co-circulating, which would further accelerate the development of resistance phenotypes comprised of combinations of mutations not previously known to co-occur in the same parasite genome.

Historically, malaria was highly prevalent in the Guangxi Zhuang Autonomous Region of China. Subsequent national anti-malarial campaigns proved highly successful in this region, stemming indigenous transmission. Recently, however, the region has experienced a dramatic rise in imported cases, owing to an increase in migrant workers who have lived in regions that remain endemic for malaria. In China, before travelling to Africa, all patients received health education conducted by local CDCs, including training about malaria transmission and personal protection. Tablets of chloroquine or piperaquine were recommended as prophylaxis.

Here, we investigated mutations of *pfdhfr* and *pfdhps* in the parasites of migrant workers returning to Shanglin, Guangxi Zhuang Autonomous Region from Africa ([@bib40]) between 2016 and 2018. As The WHO recommends that SP-IPTi has been reported from recent surveys in Africa, we confirmed that virtually no cases imported into China in this temporal interval lacked drug-resistance mutations. For context, mutations N51I, C59R and S108N were reported as universal (or nearly so) in Gabon and southeast Nigeria ([@bib3]; [@bib11]).

Notably, we report for the first time mutation I164L in patients who come from Ghana, Western Africa (12.34%) even though previous data suggested this mutation was rare in Western Africa, but more prevalent in East Africa, and only 0.6% continent-wide between 2004 and 2008 ([@bib26]). This patient had not worked outside of China in any other country excepting Ghana. No I164L had been detected in samples collected in Ghana between 2003 and 2010 ([@bib9]). We observed this mutation in only one isolate returned from DRC; this mutation was initially reported there in 2014 at a national prevalence of only 0.1% (1/1715) ([@bib27]). Hence, our survey of returning Chinese migrant laborers may indicate that this mutation is on the increase in Western Africa. For genotypes of *Pfdhfr*, five kinds of genotypes were detected in our study. Our results showed that the triple mutant **IRN**I was the predominant haplotype (\>70%) in workers returned from both Central and Western Africa. It was more prevalent among these patients (72.73%) than had been reported in Ghana in 2010, 50%--60% ([@bib9]).

In contrast to the mutations of *Pfdhfr* gene, mutations of the *Pfdhps* were observed less frequently. Mutation I431V was observed in only one isolate who returned from Ghana, the first report of this mutation from this country to date. Before working in Ghana, this patient had never traveled to any other country outside of China. The I431V mutation has previously been reported in Nigeria (46%), DRC (0.8%), and Cameroon (9.8%) ([@bib28]; [@bib27]; [@bib5]). It was widespread in Nigeria, with highest prevalence in 2014--2015 ([@bib28]). Thus, this mutation may be increasing in Western Africa. Although the effect of I431V mutation on antifolate resistance has not yet been established, it may interfere with the efficient binding of sulfadoxine, conferring increased sulfadoxine/pyrimethamine resistance ([@bib28]). The mutant A437G is associated with resistance to sulfadoxine in endemic areas and A437G selection by sulfadoxine/pyrimethamine has been previously reported during IPTi ([@bib21]; [@bib22]). The *pfdhps* A437G mutant is very common across Africa and in much of Western and Central Africa ([@bib29]). Similarly, its prevalence is over 70% in our study. According to reported survey, the prevalence of K540 E/N was high in East Africa and exceeded 50% in Uganda and Tanzania ([@bib26]; [@bib20]; [@bib1]). The WHO recommends that SP-IPTi should be implemented only when the prevalence of the K540E mutation is not exceed 50% ([@bib15]). In this study, mutant K540 E/N did not exceed 50% among migrants returned from Central and Western Africa. This may favor continued efficacy of SP-IPTi in this region, but its prevalence in these workers (12.9%) is much higher than 0.00%--3.00% prevalence reported in Ghana 2005--2010, when sulphadoxine/pyrimethamine SP first replaced chloroquine as the drug for IPTp in 2005 ([@bib9]; [@bib16]). A recent analysis concluded that IPTp efficacy was reduced when the prevalence of A581G exceeds 10% ([@bib6]). Ours is the first to suggest prevalence above that threshold in Ghana (11.6%), calling for increased surveillance to monitor the efficacy of sulfadoxine/pyrimethamine there.

Among the migrant workers studied here, the single-mutant type IS**G**KAA was the predominant haplotype in Cameroon, consistent with published data in this region during 2014--2015 ([@bib27]). This single-mutant was the most prevalent haplotype in Ghana in 2005 ([@bib29]), however, in our study, double-mutant type I**AG**KAA became the predominant haplotype (37.0%) in patients returned from Ghana, indicating growing drug resistance there, driven by an increase in A436G.

In our study, the mutation I**A**AKAA/**IRN**I is significantly higher in Central Africa, and the mutation I**AG**KAA/**IRN**I is significantly higher in Western Africa. The quadruple IS**G**KAA/**IRN**I was not obviously different from previous reports in Ghana ([@bib9]). For the first time, a high prevalence (46.2%) of quintuple *pfdhfr/pfdhps* resistance (I**AG**KAA/**IRN**I) is evident in Ghana. Available data do not definitively associate the above mutations with strong drug resistance, so the clinical implications of such new haplotypes require further study. The difference haplotype of *pfdhfr* and *pfdhps* that we have observed among imported samples may be related to differences in treatment schemes among the countries in Africa. According to reports, the IS**GE**AA/**IRN**I mutation is a significant predictor of clinical treatment failure and results in limited protective value of SP-IPTi ([@bib17]; [@bib14]). In our study, this quintuple mutant was observed in Ghana (2.2%) and Cameroon (15.7%) with rare prevalence. It may suggest that SP for IPTi and IPTp is still efficient among these countries. IS**GE**AA/**IRN**I, adds *pfdhps* 581G and/*dhfr* I164L were linked very high levels of SP failure, called 'super resistance' ([@bib13]). For the first time, we found 1.1%, 9.9% respectively for IRNI/ISGEGA and IRNL/ISGEGA.

5. Conclusions {#sec5}
==============

Taken together, our study reinforces that resistance of *P. falciparum* to SP continues to increase in Central and Western Africa, and that study of imported cases can provide valuable information on the genetic basis for such clinically-relevant phenotypic evolution in source and recipient countries. The high prevalence of resistance may now, or in the near future, abrogate the efficacy of even intermittent treatment of pregnant women or infants with sulfadoxine-pyrimethamine. This is a matter of great clinical consequence and bears on public health policy concerning treatment policy for imported malaria in China. Fortunately, ACTs treatment remains effective in China.
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